DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates
Pengxiang Qu,Oren Rom,Ke Li,Linying Jia,Xiaojing Gao,Zhipeng Liu,Shusi Ding,Mingming Zhao,Huiqing Wang,Shuangshuang Chen,Xuelian Xiong,Ying Zhao,Chao Xue,Yang Zhao,Chengshuang Chu,Bo Wen,Zuowen Zheng,Wenbin Cao,Jinpeng Zhao,Liang Bai,Sihai Zhao,Duxin Sun,Rong Zeng,Jiandie Lin,Wanqing Liu,Lemin Zheng,Jifeng Zhang,Enqi Liu,Alexandra C. Finney,Y. Eugene Chen
DOI: https://doi.org/10.1016/j.cmet.2023.03.013
IF: 29
2023-05-03
Cell Metabolism
Abstract:Qu et al. have discovered that DT-109, a tripeptide (Gly-Gly-Leu), reduces steatohepatitis, inflammation, and fibrosis in nonhuman primates with NASH. This suggests the importance of testing DT-109 in clinical trials as a potential treatment option for NASH.
cell biology,endocrinology & metabolism